Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

LAAC patients with major bleeding face worse outcomes, longer lengths of stay

The study, published in the American Journal of Cardiology, included data from nearly 20,000 patients treated in 2016 and 2017. 

Thumbnail

13% of TAVR patients develop acute kidney injury, increasing their risk of in-hospital mortality

Chronic kidney disease, congestive heart failure and liver disease are just some of the comorbidities associated with a greater risk of AKI. 

STEMI following TAVR associated with high rates of mortality, PCI failure

The analysis, published in the Journal of the American College of Cardiology, found that post-TAVR STEMI might be rare, but it can lead to substantial complications. 

Thumbnail

Abbott’s TriClip a safe, effective treatment option for severe tricuspid regurgitation

According to the real-world analysis, treatment with TriClip was associated with no major adverse events and a procedural success rate of 100%. 

Thumbnail

LAAO with Watchman device consistently lowers stroke risk after 1 year

After one year, the stroke rate for LAAO patients was just 1.53%. 

Apixaban appears safe for most TAVR patients, but questions remain

Researchers tracked data from more than 1,500 patients who underwent a successful TAVR procedure from 2016 to 2019. 

Thumbnail

A milestone for Medtronic: Low-risk TAVR patients treated with Evolut ‘doing exceptionally well’ after 2 years

The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.

Abbott’s new self-expanding TAVR system gains CE mark approval

The solution has still only been approved in the United States for investigational use. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.